The new patent covers methods of PEGylating fusion proteins and multifunctional antibodies by the DNL technique.
Immunomedics president and CEO Cynthia Sullivan said they believe PEGylation is an important delivery system for protein drugs.
"We are pleased to receive this patent, which further consolidates our protection for this new method of PEGylation, and we believe may provide additional out-licensing opportunities for us," Sullivan said.
Immunomedics develops monoclonal antibody-based products to treat cancer, autoimmune and other serious diseases.